Interestingly, one organoid model, PDTO1, the fluoresces image, exhibited increased co-expression of FABP4 and UCP2 after cetuximab treatment, suggesting that targeting these markers could disrupt cetuximab tolerance in CRC and thus enhance cellular viability (Fig. 2E; scale bar = 50 μm). Here, UCP2 is linked to colorectal carcinoma.